Biotech Companies STAB, AXSM, EXEL, NVAX, REGN, TWST and VRTX Offer Investors Growth

The biotech stock sector offers investors a chance to get in on growth in the development of drug candidates. These are designed to treat viruses like COVID-19, Alzheimer’s, or autoimmune diseases like cancers.

The best part is that many biopharmaceuticals are low-priced clinical-stage stocks that soar in value when successful. Large and small stocks have an equal chance of commercializing a drug candidate in a clinical trial. Most biotech companies have multiple drug candidates.

Place STAB Stock On Watch List As Biotech Sector Soars

Investors should put STAB stock on their Watch List as the biotech sector grows. One way to measure this is the heightened demand for commercial lab space. CBRE Group, a real estate giant, says life sciences space jumped to 31 million sq. ft. in Q4 21. That’s up from 19 million sq. ft. in Q1 21.

Lab space demand is a catalyst for this sector. And it is growing fast. Here’s an overview: 

— Statera Biopharma, Inc. (NASDAQ: STAB) is a clinical-stage biopharmaceutical company studying the treatment of pediatric Crohn’s Disease. It is also researching the treatment of patients with acute COVID-19 infection.

Michael K. Handley, the CEO, says the company has a vibrant ‘clinical-stage pipeline’ and it has recently submitted to the FDA a Phase 3 clinical trial protocol for its STAT-201 candidate for the treatment of pediatric Crohn’s Disease.

In its STAT-205 study, STAB is researching acute COVID-19 infection. STAB hopes to develop preliminary data from that study this year.

Alzheimer’s, Cigarette Smoking Addiction Researched By AXSM

— Axsome Therapeutics (NASDAQ: AXSM) is researching its drug candidates for the treatment of Alzheimer’s and smoking addiction. It also has drug candidates for the treatment of depression and migraines. It is working with the FDA on filings with the agency. 

If successful, its AXS-05 drug candidate for treating depression could be a significant driver of annualized sales volume. Analyst Motley Fool says that analysts believe it could generate as much as $2.6 billion annually.

— Elexis (NASDAQ: ELEX) is targeting kidney cancer and liver cancer. It is also working with drug company Roche (OTCMKTS: RHHBY) on developing cancer immunotherapy treatments.

Elexis is already profitable, which means it can use assets to enter and fund licensing agreements and expand drug offerings. 

Novavax Is Researching A COVID-19 Drug Candidate 

— Novavax (NASDAQ: NVAX) is researching a COVID-19 drug candidate, NVX:CoV2373. It has already secured approvals from multiple countries as well as an Emergency Use Listing from the WHO.

Novavax also has reported successful testing of its NanoFlu experimental flu vaccine. 

— Regeneron Pharmaceuticals (NASDAQ: REGN), an eye disease specialist company, enjoys lucrative partnerships with Sanofi (NASDAQ: SNY) and Bayer (OTC: BAYRY). It is also marketing and selling cancer drugs Libtayo and Zaltrap plus cancer drug Praleunt.

— Vertex Pharmaceuticals (NASDAQ: VRTX) has a virtual monopoly over cystic fibrosis (CF) drugs. Its newest drug could skyrocket its addressable CF patient population by 50% higher. Its pipeline includes more promising CF drugs already in phase 2 testing.

TWST Developing Proprietary Technology To ‘Write’ DNA On Chips

— Twist Bioscience (NASDAQ: TWST) has the smallest market cap of this group but offers investors a really unique opportunity to invest in a company developing proprietary technology for inscribing synthetic DNA on a silicon chip.

Applications for its technology apply to academic research, agriculture, healthcare, industrial chemicals and more.

Biotech stocks offer investors drug candidates and innovative research that pays off big when commercially successful. 

Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies intensify. Link to more news at

Disclaimers: Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, CGR., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated one thousand five hundred dollars via wire transfer by Compass for this article. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
Country: United States